1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

27 Jan 2021
Admin
News Article

Fuzionaire Radioisotope Technologies K.K. And Nihon Medi-Physics Enter Feasibility Study Agreement

Tokyo--(Business Wire)-- Fuzionaire Radioisotope Technologies K.K. (&Ldquo;Frit&Rdquo;) Today Announced That It Has Entered Into A Feasibility Study Agreement With Nihon Medi-Physics Co., Ltd. (&Ldquo;Nmp&Rdquo;), A Leading Radiopharmaceutical Company In Japan, Engaged In R&Amp;D, Manufacturing, And Distribution.Founded In 2019, Frit Is A Joint Venture Between Radiopharmaceutical Companies Fuzionaire Diagnostics, Inc. (&Ldquo;Fuzionaire Dx&Rdquo;) And Japan Medical Isotope Technology Development K.K. To Develop And Commercialize Fuzionaire Dx&Rsquo;S Radiopharmaceutical Technologies In Japan. Founded In 1973, Nmp Is A Joint Venture Between Sumitomo Chemical Company, Limited And Ge Healthcare.Under The Agreement, Nmp Will Evaluate The Ability Of Fuzionaire Dx&Rsquo;S Technology To Create A New Class Of Positron Emission Tomography (Pet) Radiopharmaceuticals. Fuzionaire Dx&Rsquo;S Fluorine-18 Radiolabeling Platform, Powered By A Breakthrough In Fundamental Chemistry Out Of Nobel Prize Winner Robert H. Grubbs&Rsquo; Laboratory At Caltech, Allows The Incorporation Of Fluorine-18 Into A Broad Range Of Ligands At Record-Breaking Speed.One Of Frit&Rsquo;S Priorities Is To Apply This Fluorine-18 Platform To Create New Radiopharmaceuticals That Enable The Prediction And Measurement Of Patient Responses To Cancer Immunotherapy Treatments. In Recent Years, There Have Been Extraordinary Advances In Treatments That Help Patients&Rsquo; Immune Systems Fight Cancer. However, Accurate, Optimized Patient Stratification And Selection Remains A Critical Barrier To Effective Application And Development Of Immunotherapies. Due To The Unique Capabilities Of Positron Emission Tomography &Ndash; Specific, Quantitative, Real-Time, And High-Resolution Imaging Of Markers Of Immunological Response &Ndash; New Pet Radiopharmaceuticals Have The Potential To Remove That Barrier.About Nihon Medi-Physics Co., Ltd.Nihon Medi-Physics Co., Ltd. (Nmp) Is A Leading Company For Radiopharmaceuticals In Japan, Engaged In R&Amp;D, Manufacturing, And Distribution. Nmp&Rsquo;S Stable And Reliable Supply Of Quality Products Has Contributed To Society Over The Years. With Continuous Challenges To New Business Opportunities In The &Ldquo;Development Of Theranostics,&Rdquo; &Ldquo;Application Of Digital Technology In Healthcare&Rdquo; And &Ldquo;Expansion Of Radiopharmaceutical Business In Asia,&Rdquo; Nmp Anticipates To Further Contribute To The Health And Well-Being Of Societies Into The Future.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!